2020
Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop‐Busui R, Weinstock RS. Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. Diabetes Obesity And Metabolism 2020, 22: 2045-2054. PMID: 32573927, PMCID: PMC8009602, DOI: 10.1111/dom.14121.Peer-Reviewed Original ResearchConceptsExenatide extended releaseResidual insulin productionBeta-cell functionType 1 diabetesC-peptidePlacebo groupPrimary outcomeWeek 12ER groupInsulin productionDetectable C-peptide levelsResidual beta-cell functionGLP-1 receptor agonistsRandomized placebo-controlled trialExtended releaseTotal insulin doseMean HbA1c levelPlacebo-controlled trialC-peptide levelsDetectable levelsCell functionShort-term improvementHbA1c levelsStudy drugAdverse events
2008
Primary Defects in β-Cell Function Further Exacerbated by Worsening of Insulin Resistance Mark the Development of Impaired Glucose Tolerance in Obese Adolescents
Cali AM, Man CD, Cobelli C, Dziura J, Seyal A, Shaw M, Allen K, Chen S, Caprio S. Primary Defects in β-Cell Function Further Exacerbated by Worsening of Insulin Resistance Mark the Development of Impaired Glucose Tolerance in Obese Adolescents. Diabetes Care 2008, 32: 456-461. PMID: 19106382, PMCID: PMC2646028, DOI: 10.2337/dc08-1274.Peer-Reviewed Original ResearchConceptsImpaired glucose toleranceNormal glucose toleranceBeta-cell functionBeta-cell responsivityObese adolescentsGlucose toleranceDisposition indexOral glucose tolerance testProgressive declinePre-diabetic stateGlucose tolerance testBMI z-scorePrimary defectGlucose intoleranceGlucose areaTolerance testPlasma glucoseInsulin sensitivityC-peptideInsulin secretionNonprogressorsZ-scoreNatural historyProgressorsPercent fat